Išerić Emina, Verster Joris C
Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Centre for Mental Health and Brain Sciences, Swinburne University, Melbourne, Australia.
J Allergy Clin Immunol Glob. 2024 Aug 7;3(4):100318. doi: 10.1016/j.jacig.2024.100318. eCollection 2024 Nov.
An episode of the common cold can have a significant negative impact on quality of life, mood, and daily activities. In line with this fact, there is a growing demand for health care and treatments associated with the common cold. Current treatments aim to (1) inhibit symptom severity and (2) shorten the duration of an episode of the common cold. These products include analgesics, antihistamines, and decongestants. In addition, various supplements, including vitamins, minerals, and herbs, are marketed to treat the common cold. The current products marketed for treating the common cold may reduce the severity of some (but not all) common cold symptoms, but they usually do not shorten the common cold episode. The recent indication that phenylephrine is not effective means that it will ultimately need to be removed from the over-the-counter monograph. Manufacturers will consequently need to reformulate their products and withdraw oral phenylephrine-containing products. Several newly developed common cold products are currently under investigation. These clinical trials should evaluate their efficacy and safety, as there remains a clear need for common cold products that significantly reduce both the symptom severity and the duration of episodes of the common cold.
普通感冒的发作会对生活质量、情绪和日常活动产生重大负面影响。基于这一事实，对与普通感冒相关的医疗保健和治疗的需求日益增长。当前的治疗旨在（1）抑制症状严重程度，以及（2）缩短普通感冒发作的持续时间。这些产品包括镇痛药、抗组胺药和解充血药。此外，各种补充剂，包括维生素、矿物质和草药，也被推向市场用于治疗普通感冒。目前市面上用于治疗普通感冒的产品可能会减轻一些（但不是所有）普通感冒症状的严重程度，但通常不会缩短普通感冒发作的时间。最近关于去氧肾上腺素无效的迹象意味着它最终需要从非处方药专著中移除。制造商因此需要重新配制他们的产品，并撤回含去氧肾上腺素的口服产品。目前有几种新开发的普通感冒产品正在进行研究。这些临床试验应该评估它们的疗效和安全性，因为仍然明显需要能够显著减轻普通感冒症状严重程度和缩短发作持续时间的普通感冒产品。
